Sell NowHigh
NUVL is in a Stage 4 decline with sequential lower highs and lower lows and is trading below all major EMAs and moving averages. The active Support Failure and Lower Highs & Lower Lows patterns confirm supply dominance and ongoing downtrend. With no signs of stabilization, EMA repair, or volatility contraction, selling into rallies at the 9EMA/20EMA and 50DMA is the preferred execution posture now.
- ↑PDUFA Nov 27 ’26 for neladalkib and Sep 18 ’26 for zidesamtinib could drive approvals
- ↑Total addressable oncology market >$150 B supports high revenue potential
- ↓Q2 EPS of -$6.06 and ROE -41% highlight severe losses
Full analysis →